Tuberculosis (TB), Tuberculosis Treatment Effectiveness
Conditions
Keywords
Anti-inflammatory agents, Butterfly pea flower, Cytokines, Tuberculosis therapy, Clitoria ternatea
Brief summary
The goal of this clinical trial is to learn if butterfly pea flowers (Clitoria ternatea) decocta extract works to treat as adjuvant therapy for tuberculosis in adults. It will also learn about the safety of butterfly pea flowers decocta extract. The main questions it aims to answer are: * Does butterfly pea flower extract as an adjunct TB drug therapy drug affect the profiles of interferon gamma and interleukin-10 of people with tuberculosis? * Does butterfly pea flower extract as an adjunct TB drug therapy drug affect the hematology profiles of people with tuberculosis? * Does butterfly pea flower extract as an adjunct TB drug therapy drug affect the clinical symptoms and acid-fast bacilli microscopic analysis of people with tuberculosis? * What medical problems do participants have when taking butterfly pea flower decocta extracts? Researchers will compare butterfly pea flower extract as an adjunct TB drug therapy to monotherapy TB drugs to see if adjuvant butterfly pea flowers extract works to treat tuberculosis infection in 2-month initiation phase therapy. Participants will: * Take drug butterfly pea flower extract plus TB regimen drugs consisting of rifampicin, isoniazid, pyrazinamide, and ethambutol or monotherapy TB regimen drugs only every day for 2 months * Willing to undergo treatment monitoring and visit the clinic once every 2 weeks for checkups and tests * Keep a diary of their symptoms and the number of times they use a butterfly pea flower decocta extract
Interventions
DRUGHerbal medicine
Herbal medicine from butterfly pea flower decocta extract is used as an additional TB drug therapy regimen for active TB patients during the initiation phase of treatment for 2 months.
OTHERTuberculosis (TB) treatment
The patients in anti-TB monotherapy group (Group 2) were given a regimen consisting of rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 months. This group did not receive any additional therapy.
Sponsors
Universitas Muhammadiyah Semarang
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 69 Years
Healthy volunteers
No
Inclusion criteria
* Pulmonary TB patients were positive based on the results of the Rapid Molecular Test GeneXpert M. tuberculosis (MTB)/Rifampicin (RIF), * Patients who were undergoing the initiation phase of anti-TB treatment for the first time, * Non-Multi Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) TB patients with first-line anti-TB treatment (rifampicin, isoniazid, pyrazinamide, and ethambutol), * Patients \>18 years old, * Patients who were willing to become research subjects and signed informed consent.
Exclusion criteria
* TB patients with Human Immunodeficiency Virus (HIV) positive, * Patients who did not complete the study, * Patients with non-compliance in taking medication, * Patients with comorbidities (autoimmune and cancer), * Smoking patients, * Patients contraindicated in using butterfly pea flower extract.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The interferon-gamma and interleukin-10 cytokines | From enrollment to the end of treatment at 2 months | Evaluation of the success of anti-TB therapy and anti-TB plus adjuvant butterfly pea flower therapy was carried out after completion of the 2-month initiation phase of treatment. Change Factor Analysis (CFA) for each cytokines parameter (interferon gamma or interleukin 10) was compared between the two treatment groups. Change Factor Analysis (CFA) for each therapy group was used to see whether there was an increase or decrease in cytokine concentrations after 2 months of therapy. The value was calculated from the concentration of each cytokine after treatment minus the concentration before treatment and divided by the concentration before treatment. After obtaining the CFA value for each group, the results between the groups were compared using independent t-test analysis. |
| Hematology profiles | From enrollment to the end of treatment at 2 months | For hematological profile analysis, the Change Factor Analysis (CFA) for each parameter, namely Hb (g/dL), leukocytes and platelets (cells/µL), hematocrit and granulocytes (%), and Erythrocyte Sedimentation Rate (ESR) (mm/hour) was calculated for each treatment group. Change Factor Analysis (CFA) in each therapy group was used to see whether there was an increase or decrease in the concentration of each hematological parameter after 2 months of therapy. This CFA value is calculated from the concentration of each hematological profile after treatment minus the concentration before treatment and divided by the concentration before treatment. After obtaining the CFA value for each hematology parameter in each group, the results between butterfly pea flower extract plus anti TB-regimen groups and monotherapy anti-TB regimen were compared using independent t test analysis. |
| Microscopic profiles of acid-fast bacilli (AFBs) | From enrollment to the end of treatment at 2 months | Microscopic analysis of Mycobacterium tuberculosis was carried out using Ziehl-Nielsen staining of sputum from TB patients in all therapy groups. Microscopic examination was carried out before and after treatment. The results of the examination are evaluated descriptively by seeing whether there is a decrease in the positive value of the number of colonies found during the examination. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Clinical symptoms and toxicity | From enrollment to the end of treatment at 2 months | Evaluation of clinical symptoms is carried out before and after therapy, by looking at whether there is an improvement in the symptoms of fever, cough, shortness of breath in TB patients. Hepatic toxicity was evaluated by observing whether jaundice occurred or not. |
Countries
Indonesia
Outcome results
None listed